Pfizer Anticipates ‘Fair’ Share Of Adalimumab Market In US
Company Expects To Use Interchangeability Designation To Its Advantage
Pfizer expects to make significant strides in the adalimumab market once it launches its Humira biosimilar late next year, but may not be able to enjoy its anticipated interchangeability designation until 2024.
You may also be interested in...
FDA decision ends Boehringer Ingelheim’s exclusivity for interchangeable biosimilar of Humira after just a few months. Pfizer reveals pricing and launch information for its Abrilada version of adalimumab.
An FDA decision around the timing of first interchangeable biosimilar exclusivity has brought to an end Boehringer Ingelheim’s time on the market with a unique interchangeable Humira rival, with the agency also granting interchangeability for Pfizer’s Abrilada version of adalimumab.
While Pfizer has for a couple of years now brought in annual global biosimilars turnover of more than $2bn, half-year sales suggest this may not be a sure thing in 2023 – although the firm’s strategy on adalimumab in the US could play a decisive role.